How India Exports Diazepam to the World

Diazepam, a benzodiazepine used for its anxiolytic, anticonvulsant, and muscle relaxant properties, has a well-established presence in the U.S. pharmaceutical market. The FDA has approved numerous Abbreviated New Drug Applications (ANDAs) for diazepam across various formulations, including oral tablets, injections, and rectal gels. Notably, on November 14, 2025, the FDA approved a generic version of Diastat, a rectal gel formulation of diazepam, manufactured by Navinta LLC. This approval encompasses strengths of 2.5 mg/0.5 mL, 10 mg/2 mL, and 20 mg/4 mL.

The regulatory pathway for diazepam involves submission of an ANDA, demonstrating bioequivalence to the reference listed drug (RLD). Given the mature market and the presence of multiple generic manufacturers, the U.S. market for diazepam is highly competitive. This is reflected in the export data from India, where 75 active exporters have collectively shipped diazepam to the United States, accounting for 32.2% of India's total diazepam exports. The average Free on Board (FOB) unit price stands at $11.12, indicating a competitive pricing landscape.

In the European Union, diazepam is subject to marketing authorization requirements overseen by the European Medicines Agency (EMA). The EMA mandates compliance with Good Manufacturing Practice (GMP) standards to ensure product quality and safety. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates diazepam, requiring marketing authorization and adherence to GMP. Both agencies have stringent pharmacovigilance systems to monitor the safety of diazepam post-authorization.

Diazepam is listed on the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in a basic health system. The 24th edition of the list, updated in September 2025, includes diazepam in various formulations: injection (5 mg/mL), oral liquid (2 mg/5 mL), rectal solution (2.5 mg, 5 mg, 10 mg), and tablets (5 mg, 10 mg). (who.int) This inclusion highlights diazepam's critical role in managing conditions such as anxiety, seizures, and muscle spasms.

In India, diazepam is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The Central Drugs Standard Control Organization (CDSCO) oversees its regulation, ensuring compliance with safety and efficacy standards. The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for essential medicines; however, as of March 2026, diazepam is not listed under the Drugs (Prices Control) Order (DPCO), and thus, its pricing is not subject to NPPA's ceiling price regulations. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring that the export complies with national regulations and international obligations.

The primary patents for diazepam have long expired, leading to a robust generic market with significant competition. This competitive environment is evident in the Indian export market, where 75 exporters are actively supplying diazepam to 77 destination countries. The top five exporters—VENOR PHARMA LIMITED, MYLAN LABORATORIES LIMITED, GLAND PHARMA LTD, CIRON DRUGS AND PHARMACEUTICALS PRIVATE LIMITED, and SWISS PARENTERALS LIMITED—collectively hold a substantial market share, indicating a diversified export base.

In May 2025, the FDA approved a generic version of Diastat AcuDial, a diazepam rectal gel, manufactured by Novel Labs Inc., expanding treatment options for acute repetitive seizures.

In September 2025, the WHO updated its Model List of Essential Medicines to its 24th edition, reaffirming the inclusion of diazepam in various formulations, highlighting its continued importance in global health. (who.int)

In November 2025, the FDA approved a generic version of Diastat, a diazepam rectal gel, manufactured by Navinta LLC, further increasing the availability of generic diazepam products in the U.S. market.

In December 2025, the WHO released updated guidelines on the management of acute convulsive seizures, emphasizing the use of non-parenteral routes for benzodiazepine administration, including rectal diazepam, when intravenous access is not available. (who.int)

In February 2026, the FDA approved a generic version of Valtoco, a diazepam nasal spray, expanding the range of administration routes available for diazepam.

These developments reflect ongoing efforts to enhance the accessibility and affordability of diazepam, both in the U.S. and globally, through the approval of generic formulations and the reinforcement of its essential status in medical treatment protocols.

India's pharmaceutical industry, including the production of diazepam, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of India's APIs are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance exposes the supply chain to vulnerabilities, particularly when disruptions occur in China. For instance, in July 2018, environmental regulations led to the shutdown of several Chinese chemical plants, causing a ripple effect that impacted Indian pharmaceutical manufacturers dependent on these KSMs.

The COVID-19 pandemic further highlighted these vulnerabilities. In early 2020, lockdowns and logistical challenges in China disrupted the supply of essential KSMs to India, leading to production delays and increased costs for Indian pharmaceutical companies. These events underscore the critical need for India to develop domestic capabilities in KSM and API production to mitigate such risks.

Our proprietary trade data indicates that the top five exporters of diazepam from India account for 56.4% of the total export value, with VENOR PHARMA LIMITED leading at 18.4%. This concentration suggests a moderate risk associated with supplier dependency. To address such concerns, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic manufacturing of critical APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to produce essential molecules like Penicillin G and 6-APA, marking a significant step towards reducing import dependence.

Recent geopolitical tensions have further strained the pharmaceutical supply chain. In February 2026, the closure of the Strait of Hormuz following military actions by the US and Israel led to significant disruptions in global shipping routes. This chokepoint, through which approximately 20% of the world's oil supply passes, saw a sharp decline in maritime transit, affecting not only energy supplies but also the transportation of pharmaceutical raw materials. Additionally, the Red Sea and the Bab al-Mandab Strait have experienced disruptions due to regional conflicts, further complicating shipping logistics.

These disruptions have led to increased shipping costs and delays, impacting the timely delivery of essential pharmaceutical ingredients. The FDA and EMA have issued alerts regarding potential shortages of critical medications, emphasizing the need for robust risk mitigation strategies in the pharmaceutical supply chain.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for critical APIs and KSMs to decrease reliance on imports.

• Strengthen Supply Chain Monitoring: Implement advanced tracking systems to monitor the supply chain in real-time, allowing for swift responses to disruptions.

• Develop Contingency Plans: Establish comprehensive contingency plans, including alternative shipping routes and emergency stockpiles, to mitigate the impact of geopolitical and logistical disruptions.

• Collaborate with Regulatory Bodies: Work closely with regulatory agencies to stay informed about potential shortages and compliance requirements, ensuring proactive measures can be taken.

RISK_LEVEL: HIGH